| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 7.3 | 5.1 | 4.8 |
| Other income | 0.3 | 0.3 | 0.0 |
| Total income | 7.6 | 5.5 | 4.8 |
| Profit before exceptional items & tax | 0.3 | 0.9 | 0.1 |
| Profit before tax | 0.3 | 0.9 | 0.1 |
| Net profit | 0.2 | 0.6 | 0.0 |
| Operating margin | 3.9% | 16.4% | 2.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | -66.70% |
|---|---|
| Revenue, year on year | +52.10% |
| Operating profit, year on year | -100.00% |
| Operating profit, quarter on quarter | -100.00% |
BSE results filing, NSE: BERLDRG. Figures extracted from the filing.
Beryl Drugs Ltd: key numbers
- Share price
- ₹25.55
- Market cap
- ₹12.96 Cr
- Revenue (annual)
- ₹18.82 Cr
- Net profit (annual)
- ₹0.42 Cr
- P/E (TTM)
- 20.8×Sector 47.3×
- Promoter holding
- 27.82%+0.34% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Beryl Drugs Ltd
All →Beryl Drugs Annual Report
Beryl Drugs Ltd has submitted its 33rd Annual Report for the financial year 2025-26, scheduled for its upcoming Annual General Meeting.
Beryl Drugs Annual General Meeting
Beryl Drugs Ltd has announced the closure of its register of members from September 23 to September 29, 2026, for its 33rd Annual General Meeting.
Beryl Drugs Board Meeting Outcome
Beryl Drugs Limited approved items for its 33rd Annual General Meeting and a proposal to increase material related party transaction limits.
Beryl Drugs Board Meeting Date
Beryl Drugs Ltd has scheduled a Board Meeting for September 2, 2026, to approve the Board report and matters related to its 33rd Annual General Meeting.
Beryl Drugs Promoter Buying
Sudhir Sethi, a promoter of Beryl Drugs Limited, acquired 3,000 equity shares via market transactions. This acquisition increases the promoter's total stake from 10.08% to 10.14%.
Beryl Drugs Board Meeting Outcome
Beryl Drugs Ltd's board meeting on August 11, 2026, approved the unaudited financial results for the quarter ended June 30, 2026.